CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
APAC
CANADA

About Us

Conference

Partner With Us

  • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    BioTech
    Cell and Gene Therapy
    Clinical Trial
    Drug Discovery and Development
    Life Science AI
    Regenerative Medicine
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    Blood Bank
    CDMO
    Clinical Laboratory
    CRO
    Life Science Testing
    Skin Care
    Supplements
  • Business Services
    Life Science Consulting
    Life Science Facility Service
    Life Science Financial Services
    Life Science Marketing
    Life Science Recruitment Firms
    Pharma Wholesale and Distribution
    Pharmacy Management
    Regulatory and Compliance
    Regulatory Services
  • Leadership Perspectives
  • Innovation Insights
  • Research
  • News
  • Magazines
  • CXO Awards
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our Life Sciences Review Advisory Board.

NSF International

Robyn Meurant, Executive Director, Regulatory Services, IVDs and Medical Devices

Maintaining Regulatory Impacts

Robyn Meurant

Robyn Meurant

The Road Ahead: Unforeseen Hurdles in EU IVD Regulation


While there is general industry agreement about the positive intent of EU MDR and IVDR, many manufacturers are now scrambling to understand the terrain of the road going forward–and they are right to be concerned. There are several factors that will powerfully impact their ability to meet strategic and regulatory timelines; some result from shortsightedness, and some from the simple fact that it is difficult to stay abreast of the change while still driving their business forward.


Scope of Regulatory Impact


The new regulation has a far-reaching impact. Strengthened quality system requirements, enhanced product traceability through the need for product identifiers, explicit formalized relationships with the supply chain, reporting in the EUDAMED database, proactive post-market surveillance, performance evaluation reports, evidence of scientific validity, and clinical performance are just a few of the major changes. Top-level management must realize the impact in terms of time, money, and portfolio on the whole of their business, and drive the implementation accordingly.


Overestimating Notified Body Access


While most manufacturers have begun to see the light, the impact of limited notified body access may not be yet fully grasped. Notified bodies are designated according to “assessment” codes that define the scope of their activities. There are over 80 IVD assessment codes, and upwards of ten codes may apply to a single device. It is very unlikely that every notified body will be designated for each of these codes. Thus, it is important to book your assessment with a notified body that you assume will have all codes relevant to your device in the scope of their designation – an independent consultant can help you find the right partnership if needed. Despite recent hopeful news about new notified body players entering the market, the destabilizing imbalance between demand and supply is likely to wreak especial havoc on small to medium-sized companies.


Underestimating the Gap


Many IVD manufacturers have a broad range of products, but they do not understand the full extent of costs in terms of remediation for existing products. A gap assessment of technical documentation against the regulatory requirements is an obvious and excellent first step. If a manufacturer has been relying on data generated for a 510(k) premarket notification, remember that demonstration of substantial equivalence is rarely the basis of, and may not meet the requirements for compliance in the EU. Also, the number of requirements to be met is not highly impacted by the risk class. It is only the amount of evidence per requirement that may change, dependent on factors including the intended purpose and degree of novelty.


"Top level management must realize regulatory impact in terms of time, money, and portfolio on the whole of their business, and drive the implementation accordingly"


Certification-driven Costs


Remember to also factor in the costs of certification itself. It is not yet known how many devices can be grouped together for a single conformity assessment certificate with a notified body. Each certificate will cost substantially. While the general requirements for each classification remain the same, the number of applications needed varies by class and by product type. There is an allowance for product grouping, but some product types require individual, per-product application. Unanticipated additional applications will mean unanticipated costs.


The impending complexities in the regulatory navigation and lack of notified body access could make the situation untenable for companies with limited technical files or insufficient capital, and time is not on the manufacturers’ side. The optimal time to engage with a notified body and/or perform that critical gap analysis is already past. Seek expert help if in any doubt. Manufacturers who have already begun will be one step ahead of their competition. Those that have yet to start may find themselves woefully behind, with the odds of catching up shrinking each day.


The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.
The Leadership Perspectives forum brings together voices shaping the future of life sciences. It features leaders who are advancing change across the industry through strategic leadership and applied insight.
EDITOR'S CHOICE
  • Willis Towers Watson

    ICON [NASDAQ: ICLR]

    The Significant Increase in Demand for Clinical Research Associates (CRAs)

    Helen Yeardley, Executive Vice President, ICON [NASDAQ: ICLR]

  • Willis Towers Watson

    PacBio [NASDAQ: PACB]

    The Talent - Culture Continuum: How to Manage an Innovation Culture Amid Growth and Change

    Alvin Hom, Head of Global Talent Acquisition, PacBio [NASDAQ: PACB]

  • Willis Towers Watson

    Repligen Corp [NASDAQ: RGEN]

    Gene Therapy-Therapeutic Viral Vectors; Manufacturing, Challenges, and Innovation

    Rachel Legmann, PhD, Senior Director of Technology, Gene Therapy, Repligen Corp

  • Willis Towers Watson

    Ionis Pharmaceuticals [NASDAQ: IONS]

    Bridging the Diversity Divide

    Victoria Sanjurjo, Medical Director, Clinical Development, Ionis Pharmaceuticals, Inc [NASDAQ: IONS]

Life Sciences Review
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/leadership-perspective/maintaining-regulatory-impacts-nwid-633.html